SG11202103806VA - 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament - Google Patents

4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Info

Publication number: SG11202103806VA
Authority: SG; Singapore
Prior art keywords: pyrazin; ylmethyl; medicament; morpholine derivatives; morpholine
Prior art date: 2018-10-17

Application number

SG11202103806VA

Other languages

English (en)

Inventor

Riccardo Giovannini

Angelo Ceci

Cornelia Dorner-Ciossek

Roland Pfau

Dieter Wiedenmayer

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-10-17

Filing date

2019-10-16

Publication date

2021-05-28

2019-10-16 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2021-05-28 Publication of SG11202103806VA publication Critical patent/SG11202103806VA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

SG11202103806VA 2018-10-17 2019-10-16 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament SG11202103806VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP18200943		2018-10-17
PCT/EP2019/078027 WO2020079039A1 (fr)	2018-10-17	2019-10-16	Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament

Publications (1)

Publication Number	Publication Date
SG11202103806VA true SG11202103806VA (en)	2021-05-28

Family

ID=63878518

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202103806VA SG11202103806VA (en)	2018-10-17	2019-10-16	4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Country Status (38)

Country	Link
US (3)	US11166958B2 (fr)
EP (1)	EP3867244B1 (fr)
JP (1)	JP7093468B2 (fr)
KR (1)	KR102840105B1 (fr)
CN (1)	CN112888685B (fr)
AR (1)	AR116711A1 (fr)
AU (1)	AU2019362330B2 (fr)
BR (1)	BR112021004993A2 (fr)
CA (1)	CA3113308A1 (fr)
CL (1)	CL2021000858A1 (fr)
CO (1)	CO2021004612A2 (fr)
CR (1)	CR20210184A (fr)
DK (1)	DK3867244T3 (fr)
DO (1)	DOP2021000069A (fr)
EA (1)	EA202191014A1 (fr)
EC (1)	ECSP21027009A (fr)
ES (1)	ES2940184T3 (fr)
FI (1)	FI3867244T3 (fr)
HR (1)	HRP20230249T1 (fr)
HU (1)	HUE061891T2 (fr)
IL (1)	IL282142B2 (fr)
JO (1)	JOP20210075B1 (fr)
LT (1)	LT3867244T (fr)
MA (1)	MA53898B1 (fr)
MX (1)	MX2021004418A (fr)
MY (1)	MY205127A (fr)
NZ (1)	NZ773672A (fr)
PE (1)	PE20211278A1 (fr)
PH (1)	PH12021550834A1 (fr)
PL (1)	PL3867244T3 (fr)
PT (1)	PT3867244T (fr)
RS (1)	RS63988B1 (fr)
SA (1)	SA521421756B1 (fr)
SG (1)	SG11202103806VA (fr)
SI (1)	SI3867244T1 (fr)
TW (1)	TWI828779B (fr)
UA (1)	UA128408C2 (fr)
WO (1)	WO2020079039A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW202112378A (zh) *	2019-06-04	2021-04-01	德商百靈佳殷格翰國際股份有限公司	嘌呤衍生物及其作為藥物之用途
WO2025233259A1 (fr)	2024-05-07	2025-11-13	Boehringer Ingelheim International Gmbh	Composé destiné à être utilisé dans le traitement de la dépression, d'un trouble obsessionnel compulsif, d'un trouble de stress post-traumatique et/ou d'un trouble de la personnalité borderline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6495561B2 (en)	1999-10-29	2002-12-17	Merck & Co., Inc.	2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
WO2002080928A1 (fr) *	2001-04-03	2002-10-17	Merck & Co., Inc.	Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
ES2312603T3 (es) *	2001-07-24	2009-03-01	Richter Gedeon Nyrt	Derivados de piperidina como antagonistas del receptor nmda.
WO2007067511A2 (fr) *	2005-12-06	2007-06-14	Merck & Co., Inc.	Antagonistes de recepteur de prokineticine de morpholine-carboxamide
US20110319416A1 (en) *	2009-01-28	2011-12-29	Emory University	Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2012128582A2 (fr) *	2011-03-23	2012-09-27	Hyundai Pharm Co., Ltd.	Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant
ES2599553T3 (es)	2012-10-18	2017-02-02	F. Hoffmann-La Roche Ag	Derivados de etinilo como moduladores de la actividad del receptor mGluR5
EP3110794A1 (fr) *	2014-02-27	2017-01-04	Merck Patent GmbH	Composés hétérocycliques en tant qu'inhibiteurs du canal nav, et leurs utilisations
WO2016029146A1 (fr)	2014-08-22	2016-02-25	University Of Washington	Inhibiteurs spécifiques de la méthionyl-tarn synthétase
ES2822830T3 (es) *	2015-10-14	2021-05-05	Bristol Myers Squibb Co	Antagonistas selectivos de NR2B

2019
- 2019-10-16 MY MYPI2021001774A patent/MY205127A/en unknown
- 2019-10-16 CR CR20210184A patent/CR20210184A/es unknown
- 2019-10-16 HU HUE19786343A patent/HUE061891T2/hu unknown
- 2019-10-16 AU AU2019362330A patent/AU2019362330B2/en active Active
- 2019-10-16 IL IL282142A patent/IL282142B2/en unknown
- 2019-10-16 KR KR1020217014924A patent/KR102840105B1/ko active Active
- 2019-10-16 ES ES19786343T patent/ES2940184T3/es active Active
- 2019-10-16 FI FIEP19786343.4T patent/FI3867244T3/fi active
- 2019-10-16 US US16/654,030 patent/US11166958B2/en active Active
- 2019-10-16 TW TW108137247A patent/TWI828779B/zh active
- 2019-10-16 AR ARP190102937A patent/AR116711A1/es unknown
- 2019-10-16 JP JP2021520981A patent/JP7093468B2/ja active Active
- 2019-10-16 PE PE2021000513A patent/PE20211278A1/es unknown
- 2019-10-16 CA CA3113308A patent/CA3113308A1/fr active Pending
- 2019-10-16 BR BR112021004993-2A patent/BR112021004993A2/pt unknown
- 2019-10-16 NZ NZ773672A patent/NZ773672A/en unknown
- 2019-10-16 RS RS20230140A patent/RS63988B1/sr unknown
- 2019-10-16 DK DK19786343.4T patent/DK3867244T3/da active
- 2019-10-16 EA EA202191014A patent/EA202191014A1/ru unknown
- 2019-10-16 MX MX2021004418A patent/MX2021004418A/es unknown
- 2019-10-16 WO PCT/EP2019/078027 patent/WO2020079039A1/fr not_active Ceased
- 2019-10-16 CN CN201980067936.7A patent/CN112888685B/zh active Active
- 2019-10-16 PL PL19786343.4T patent/PL3867244T3/pl unknown
- 2019-10-16 SI SI201930465T patent/SI3867244T1/sl unknown
- 2019-10-16 UA UAA202102481A patent/UA128408C2/uk unknown
- 2019-10-16 LT LTEPPCT/EP2019/078027T patent/LT3867244T/lt unknown
- 2019-10-16 HR HRP20230249TT patent/HRP20230249T1/hr unknown
- 2019-10-16 SG SG11202103806VA patent/SG11202103806VA/en unknown
- 2019-10-16 EP EP19786343.4A patent/EP3867244B1/fr active Active
- 2019-10-16 PT PT197863434T patent/PT3867244T/pt unknown
- 2019-10-16 MA MA53898A patent/MA53898B1/fr unknown
2021
- 2021-04-07 CL CL2021000858A patent/CL2021000858A1/es unknown
- 2021-04-13 CO CONC2021/0004612A patent/CO2021004612A2/es unknown
- 2021-04-13 JO JOJO/P/2021/0075A patent/JOP20210075B1/ar active
- 2021-04-14 SA SA521421756A patent/SA521421756B1/ar unknown
- 2021-04-14 PH PH12021550834A patent/PH12021550834A1/en unknown
- 2021-04-16 DO DO2021000069A patent/DOP2021000069A/es unknown
- 2021-04-16 EC ECSENADI202127009A patent/ECSP21027009A/es unknown
- 2021-08-27 US US17/458,631 patent/US20210393644A1/en not_active Abandoned
2025
- 2025-01-15 US US19/022,358 patent/US20250345341A1/en active Pending

Also Published As

Publication number	Publication date
IL282142A (en)	2021-05-31
CO2021004612A2 (es)	2021-04-30
NZ773672A (en)	2024-12-20
EP3867244B1 (fr)	2023-01-18
ECSP21027009A (es)	2021-05-31
AR116711A1 (es)	2021-06-02
JP7093468B2 (ja)	2022-06-29
EA202191014A1 (ru)	2021-11-09
EP3867244A1 (fr)	2021-08-25
FI3867244T3 (fi)	2023-03-20
CR20210184A (es)	2021-05-26
DK3867244T3 (da)	2023-05-01
TWI828779B (zh)	2024-01-11
MY205127A (en)	2024-10-03
KR20210079325A (ko)	2021-06-29
TW202031262A (zh)	2020-09-01
KR102840105B1 (ko)	2025-07-31
PL3867244T3 (pl)	2023-05-22
SA521421756B1 (ar)	2023-02-12
HRP20230249T1 (hr)	2023-04-14
CL2021000858A1 (es)	2021-10-01
CA3113308A1 (fr)	2020-04-23
AU2019362330A1 (en)	2021-04-08
LT3867244T (lt)	2023-03-10
US20200121691A1 (en)	2020-04-23
JP2022505080A (ja)	2022-01-14
SI3867244T1 (sl)	2023-04-28
MA53898A (fr)	2022-01-26
AU2019362330B2 (en)	2024-03-28
PE20211278A1 (es)	2021-07-19
RS63988B1 (sr)	2023-03-31
IL282142B2 (en)	2024-04-01
PH12021550834A1 (en)	2021-10-04
PT3867244T (pt)	2023-02-22
CN112888685B (zh)	2023-09-22
MX2021004418A (es)	2021-07-06
ES2940184T3 (es)	2023-05-04
BR112021004993A2 (pt)	2021-06-08
US20250345341A1 (en)	2025-11-13
US20210393644A1 (en)	2021-12-23
US11166958B2 (en)	2021-11-09
IL282142B1 (en)	2023-12-01
MA53898B1 (fr)	2023-03-31
WO2020079039A1 (fr)	2020-04-23
CN112888685A (zh)	2021-06-01
HUE061891T2 (hu)	2023-09-28
UA128408C2 (uk)	2024-07-03
JOP20210075A1 (ar)	2023-01-30
JOP20210075B1 (ar)	2024-12-22
DOP2021000069A (es)	2021-05-31

Publication	Publication Date	Title
EP3706741A4 (fr)	2022-03-30	Composition pharmaceutique et utilisation associée
GB2552063B (en)	2021-10-27	Medical scope accessory, medical scopes comprising the accessory, and use thereof
IL276952A (en)	2020-10-29	History of 4,2-diaminoquinazolines and their medicinal uses
IL257173A (en)	2018-06-28	New insulin histories and their medical uses
IL273339A (en)	2020-05-31	Griseofulbin compound and its medical use
SG11201908281VA (en)	2019-10-30	Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
IL277749A (en)	2020-11-30	Palladianolide compounds and their use
GB201715194D0 (en)	2017-11-01	Compounds and their therapeutic use
GB201813312D0 (en)	2018-09-26	Compounds and their therapeutic use
IL276814A (en)	2020-10-29	Indazole-3-carboxamides converted in 5-heteroaryl and their preparation and use
IL276323A (en)	2020-09-30	4-Methyldihydropyrimidinone compounds and their pharmaceutical use
GB2590189B (en)	2022-10-19	Lycorine derivative, and pharmaceutical composition and use thereof
SG11202008543RA (en)	2020-10-29	Pyrrolidineamide derivatives and uses thereof
IL282526A (en)	2021-06-30	5-Azaindazole history and their use
IL282527A (en)	2021-06-30	5-Azaindazole history and their use
IL280644A (en)	2021-03-25	Magnesium serine compound and its use
SG11202103806VA (en)	2021-05-28	4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
IL274868A (en)	2020-07-30	History of imidazopyridine and their use as medicine
ZA202000959B (en)	2021-08-25	Adamantylmethylamine derivative and use thereof as pharmaceutical
IL292646A (en)	2022-07-01	Pharmaceutical combination and its use
EP3227293A4 (fr)	2018-09-12	Dérivés de 6.7-cyclomorphinane et leur utilisation
PL3860615T3 (pl)	2024-12-23	Kompozycja doustna zawierająca B-escynę i jej zastosowanie
GB201902087D0 (en)	2019-04-03	Medicament and the use thereof
GB201802743D0 (en)	2018-04-04	Medicament and use thereof
IL283540A (en)	2021-07-29	Dock1 inhibitory compound and use thereof